BioScience Trends
Online ISSN : 1881-7823
Print ISSN : 1881-7815
ISSN-L : 1881-7815
Original Article
Methyl-CpG binding domain protein 3: a new diagnostic marker and potential therapeutic target of melanoma
Takayuki IshibashiIkko KajiharaSatoru MizuhashiHaruka KuriyamaToshihiro KimuraHisashi KanemaruKatsunari MakinoAzusa MiyashitaJun AoiTakamitsu MakinoSatoshi FukushimaKanako KitaHironobu Ihn
Author information
Keywords: MBD3, melanoma, N-cadherin, MMP-2
JOURNAL FREE ACCESS

2020 Volume 14 Issue 5 Pages 390-395

Details
Abstract

Methyl-CpG binding domain protein 3 (MBD3) belongs to the methyl-CpG binding protein family. MBD3 facilitates the initiation of neural stem cell reprogramming. Melanoma originates in melanocytes derived from neural crest stem cells; therefore, we investigated the role of MBD3 in melanoma. MBD3 was overexpressed in melanoma compared with pigmented nevi. MBD3 knockdown had no effect on the proliferation of melanoma cells (A375 and A2058 cells). Contrarily, it significantly reduced the migration and invasion of A375 cells, but had no significant effect on A2058 cells. Furthermore, MBD3 knockdown reduced N-cadherin protein levels and matrix metalloproteinase-2 (MMP-2) activity in A375 cells, but had no significant effect on A2058 cells. Based on these results, the MBD3 expression level may be a useful biomarker for the diagnosis of melanoma. Thus, MBD3 has potential as a novel therapeutic target for some melanoma patients.

Content from these authors
© 2020 International Research and Cooperation Association for Bio & Socio-Sciences Advancement
Previous article Next article
feedback
Top